多替拉韦/拉米夫定与多替拉韦联合恩曲他滨/丙酚替诺福韦在初治HIV感染者中精浆HIV-1-RNA的衰减动力学比较
本亚研究为IV期随机临床试验,比较多替拉韦/拉米夫定与多替拉韦联合丙酚替诺福韦/恩曲他滨在初治HIV感染者男性生殖道的活性。第12周时两组精浆HIV-1-RNA不可检出比例无差异,血精浆HIV-1-RNA衰减无显著差异。
要点
- 第12周时每组仅1例精浆HIV-1-RNA可检出(多替拉韦+丙酚替诺福韦/恩曲他滨组141拷贝/mL;多替拉韦/拉米夫定组61拷贝/mL)。
- 两组血HIV-1-RNA随时间衰减无显著差异(F=0.452,P=0.662)。
- 两组精浆HIV-1-RNA随时间衰减无显著差异(F=1.147,P=0.185)。
核心结论
- 治疗12周后,初治HIV感染者启动多替拉韦/拉米夫定与多替拉韦+丙酚替诺福韦/恩曲他滨相比,精浆HIV-1-RNA不可检出百分比无差异。
研究设计与样本
- IV期随机临床试验(ClinicalTrials.gov标识NCT04295460)的亚研究,比较多替拉韦/拉米夫定与多替拉韦+丙酚替诺福韦/恩曲他滨在男性生殖道的活性。
- 纳入无症状、无性传播疾病、初治HIV感染者,CD4+ T细胞计数>200细胞/mm3,血浆HIV-1-RNA水平>5000且<500000拷贝/mL,按1:1随机分配至多替拉韦+丙酚替诺福韦/恩曲他滨组或多替拉韦/拉米夫定组。
- 在基线和第4、8、12、24周采集血血浆和精浆,使用Cobas 6800系统(Roche Diagnostics)检测HIV-1-RNA,检测下限为20拷贝/mL。
- 主要疗效终点为第12周意向性治疗分析中精浆HIV-1-RNA不可检出的受试者比例。
- 多替拉韦+丙酚替诺福韦/恩曲他滨组15例、多替拉韦/拉米夫定组16例纳入分析。
主要发现
- 基线精浆病毒载量:多替拉韦+丙酚替诺福韦/恩曲他滨组4.81(4.30-5.43),多替拉韦/拉米夫定组4.76(4.09-5.23),P=0.469。
- 第12周时,每组仅1例精浆HIV-1-RNA可检出(多替拉韦+丙酚替诺福韦/恩曲他滨组141拷贝/mL;多替拉韦/拉米夫定组61拷贝/mL)。
- 基于估计均值,两组血血浆HIV-1-RNA随时间衰减无显著差异(F=0.452,P=0.662)。
- 基于估计均值,两组精浆HIV-1-RNA随时间衰减无显著差异(F=1.147,P=0.185)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This was a substudy of a Phase IV, randomized clinical trial (ClinicalTrials.gov identifier: NCT04295460) aiming to compare the activity of dolutegravir/lamivudine versus dolutegravir plus tenofovir alafenamide/emtricitabine (DTG + TAF/FTC) in the male genital tract. METHODS: Participants were asymptomatic adults without sexually transmitted diseases, treatment-naive people living with HIV (PLWH), with CD4+ T cell counts >200 cells/mm3 and plasma HIV-1-RNA levels >5000 and <500 000 copies/mL, randomized (1:1) to DTG + TAF/FTC or dolutegravir/lamivudine. Blood plasma (BP) and seminal plasma (SP) were collected at baseline and Weeks 4, 8, 12 and 24. HIV-1-RNA was measured in BP and SP using the Cobas 6800 system (Roche Diagnostics) with a lower detection limit of 20 copies/mL. The primary efficacy endpoint was the proportion of subjects with undetectable SP HIV-1-RNA at Week 12 by intention-to-treat analysis. RESULTS: Fifteen participants in the DTG + TAF/FTC and 16 in the dolutegravir/lamivudine arms were analysed, with basal SP viral load of 4.81 (4.30-5.43) and 4.76 (4.09-5.23), P = 0.469, respectively. At Week 12, only one participant in each treatment arm had a detectable SP HIV-1-RNA (DTG + TAF/FTC, 141 copies/mL; dolutegravir/lamivudine, 61 copies/mL). Based on the estimated means, there was no significant difference in the decay of HIV-1-RNA in both BP and SP over time between the two arms of treatment (F = 0.452, P = 0.662, and F = 1.147, P = 0.185, respectively). CONCLUSIONS: After 12 weeks of treatment, there were no differences in the percentage of undetectable SP HIV-1-RNA in naive PLWH who started dolutegravir/lamivudine compared with DTG + TAF/FTC.
引用
- Saborido-Alconchel A, Serna-Gallego A, Lopez-Cortes LE, et al. Decay kinetics of HIV-1-RNA in seminal plasma with dolutegravir/lamivudine versus dolutegravir plus emtricitabine/tenofovir alafenamide in treatment-naive people living with HIV. J Antimicrob Chemother. 2023. PMID: 37545387. doi:10.1093/jac/dkad245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。